HU-x Synthetic Cannabinoids Cannabinoid Research

HU-x Synthetic Cannabinoids Research Dashboard


Primary Studies


Related Studies


Total Studies

Clinical Studies


Clinical Meta-analyses


Double-blind human trials


Clinical human trials

Pre-Clinical Studies




Animal studies


Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 147 studies associated with HU-x Synthetic Cannabinoids.

Here is a small sampling of HU-x Synthetic Cannabinoids studies by title:

Components of the HU-x Synthetic Cannabinoids Research Dashboard

  • Top medical conditions associated with HU-x Synthetic Cannabinoids
  • Proven effects in clinical trials for HU-x Synthetic Cannabinoids
  • Receptors associated with HU-x Synthetic Cannabinoids
  • Individual study details for HU-x Synthetic Cannabinoids

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - HU-x Synthetic Cannabinoids

Description of HU-x Synthetic Cannabinoids

The HU-x series are synthetic cannabinoids that carry the initials based on their place of discovery Hebrew University, Israel.

Here we focus on the (+) and (-) cannabinoid enantiomers of 7-hydroxy-delta-6-tetra-hydrocannabinol-dimethylheptyl i.e., HU-210 and HU-211.

Initially developed and/or characterized by Mechoulam et al., (1988), HU-210 and HU-211 are two of several diverse members of the HU-family that have attracted significant attention in the international research community. For instance, HU-210 has full agonist activity at CB1 and CB2, while the (+) enantiomer, i.e., HU-211 does not, but instead acts as via different pathways such as an N-Methyl-D-aspartate (NMDA) antagonist.

Other members that may offer clinical insights may include HU-308 (CB2 agonism), HU-331, HU-444, HU-580, HU-671, HU-910, HU-914.

Other Names:

HU Family Synthetic Cannabinoids

7-hydroxy-delta-6-tetra-hydrocannabinol-dimethylheptyl or 7-OH-delta-6-THC-DMH

HU-210 [(-)-enantiomer] (-)-7-OH-delta-6-THC-DMH (N. Titishov et al., 1989)

HU-211 [(+)-enantiomer]; (aka Dexanabinol) (+)-7-OH-delta-6-THC-DMH (N. Titishov et al., 1989)

HU-x Synthetic Cannabinoids Properties and Effects

HU-210 (psychoactive) may: 

  • Induce antidepressant-like effect (G. Fang et al., 2023)

  • Not induce chronic depression, despite inducing short-term stress reactivity (M. Farinha-Ferreira et al., 2022)

  • Improve circadian parameters in retinal dystrophic rats (P. Lax et al., 2019) 

  • Improve neurological outcome of patients with traumatic brain injuries (D. Farrell et al., 2018)

  • Generate protective effects in experimental colitis (S. Lin et al., 2017)

  • Higher doses interfere with spontaneous object recognition (M. Sticht et al., 2015)

  • Induce neuroprotection in retinal degeneration (P. Lax et al., 2014)

  • Mitigate neuro-inflammation and oxidative stress with relevance to PD (Y. Chung et al., 2011)

  • Protect against mutant huntingtin-induced cell death (E. Scotter et al., 2010)

  • Modulate endocrine function (A. Ottani et al., 2001)

  • Have dose-dependent stimulant or inhibitory immune activity (A. Ottani et al., 2001)

  • Deceases sexual activities in the test animals (F. Ferrari et al., 2000) 

  • Result in loss of body weight (D. Giuliani et al., 2000)

  • Antiemetic (F. Ferrari et al., 1999)

  • Changes in cognition/memory (F. Ferrari et al., 1999)

  • Induced antinociception (W. Martin et al., 1998)

  • Exhibit suppression of both phases of the primary humoral immune response (R. Mechoulam et al., 1989)

  • Induced changes in cognition, hypothermia, analgesia, ataxia (R. Mechoulam et al., 1989)

HU-211 (non-psychoactive) may:

  • Modulates curcumin/CB1 with potential anti-depressant effects (X. He et al., 2017; X. He et al., 2016)

  • No psychoactivity (R. Mechoulam et al., 1993)

  • May be neuroprotective N-methyl-D-aspartate receptor-mediated neurotoxicity (R. Mechoulam et al., 1993)

  • Inhibition of cisplatin-induced emesis (R. Mechoulam et al., 1989)

HU-x Synthetic Cannabinoids Receptor Binding

Endocannabinoid System (ECS) and HU-210:

  • CB1 full agonist with a Ki ~0.7nM (V. Showalter et al., 1996)

  • CB2 full agonist with a Ki ~0.7nM (V. Showalter et al., 1996)

Endocannabinoidome (eCBome) and HU-210:

  • Modulator at Ca2+ channel (A. Ottani et al., 2001)

Endocannabinoid System (ECS) and HU-211:

  • Modulates curcumin/CB1 with potential anti-depressant effects (X. He et al., 2017)

Endocannabinoidome (eCBome) and HU-211:

  • A putative modulator at glutamate receptors (Zhixiong Ma et al., 2022)

  • Modulates curcumin/CB1 with anti-depressant effects (X. He et al., 2017) 

  • Inhibitor of the N-methyl-D-aspartate (NMDA) receptors (R. Mechoulam et al., 1993)

Ki legend:

  • Full/strong agonist Ki ~1-9nM

  • Moderate agonist Ki ~10-99nM

  • Weak agonist Ki ~100-999nM

  • Very weak agonist Ki ~1,000-up nM

(The reader is reminded that a smaller Ki is associated with the strongest effects.)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.